Alterations in Cortical Excitation and Inhibition in Genetic Mouse Models of Huntington's Disease

Mental Retardation Research Center, David Geffen School of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles, Los Angeles, CA 90095, USA.
The Journal of Neuroscience : The Official Journal of the Society for Neuroscience (Impact Factor: 6.75). 09/2009; 29(33):10371-86. DOI: 10.1523/JNEUROSCI.1592-09.2009
Source: PubMed

ABSTRACT Previously, we identified progressive alterations in spontaneous EPSCs and IPSCs in the striatum of the R6/2 mouse model of Huntington's disease (HD). Medium-sized spiny neurons from these mice displayed a lower frequency of EPSCs, and a population of cells exhibited an increased frequency of IPSCs beginning at approximately 40 d, a time point when the overt behavioral phenotype begins. The cortex provides the major excitatory drive to the striatum and is affected during disease progression. We examined spontaneous EPSCs and IPSCs of somatosensory cortical pyramidal neurons in layers II/III in slices from three different mouse models of HD: the R6/2, the YAC128, and the CAG140 knock-in. Results revealed that spontaneous EPSCs occurred at a higher frequency, and evoked EPSCs were larger in behaviorally phenotypic mice whereas spontaneous IPSCs were initially increased in frequency in all models and subsequently decreased in R6/2 mice after they displayed the typical R6/2 overt behavioral phenotype. Changes in miniature IPSCs and evoked IPSC paired-pulse ratios suggested altered probability of GABA release. Also, in R6/2 mice, blockade of GABA(A) receptors induced complex discharges in slices and seizures in vivo at all ages. In conclusion, altered excitatory and inhibitory inputs to pyramidal neurons in the cortex in HD appear to be a prevailing deficit throughout the development of the disease. Furthermore, the differences between synaptic phenotypes in cortex and striatum are important for the development of future therapeutic approaches, which may need to be targeted early in the development of the phenotype.

Download full-text


Available from: Carlos Cepeda, Aug 19, 2015
  • Source
    • "Thus, a recent targeted rescue study in a mouse model of HD provided evidence that it is the combination of mutant Huntingtin in cortical neurons and in MSNs that accounts for MSN degeneration and striatal dysfunction (Wang et al., 2014). HD might therefore initially involve deficits in neurons synapsing onto MSNs (Cummings et al., 2009; Thomas et al., 2011), but the degeneration is then most pronounced in MSNs (Cowan et al., 2008). In other words, mutant Huntingtin might not be sufficient to cause loss of excitation and degeneration of MSNs in HD, but combined with loss of critical excitatory inputs by cortical neurons, it then causes degeneration in MSNs (Figure 2). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neurodegenerative diseases (NDDs) involve years of gradual preclinical progression. It is widely anticipated that in order to be effective, treatments should target early stages of disease, but we lack conceptual frameworks to identify and treat early manifestations relevant to disease progression. Here we discuss evidence that a focus on physiological features of neuronal subpopulations most vulnerable to NDDs, and how those features are affected in disease, points to signaling pathways controlling excitation in selectively vulnerable neurons, and to mechanisms regulating calcium and energy homeostasis. These hypotheses could be tested in neuronal stress tests involving animal models or patient-derived iPS cells. Copyright © 2015 Elsevier Inc. All rights reserved.
    Neuron 03/2015; 85(5):901-910. DOI:10.1016/j.neuron.2014.12.063 · 15.98 Impact Factor
  • Source
    • "To fully assess the pattern of the vasculature or arteries, the ROIs were sized 600 × 450 and 900 × 400 μm 2 for CoIV-stained and αSMA-stained sections, respectively. According to a mouse brain atlas (Paxinos and Franklin, 2004), these two ROIs are located in the somatosensory cortex and dorsocentral striatum, respectively (approximately bregma 0.5 mm, lateral 2.2 mm, and depth 1.2 mm, and bregma 0.5 mm, lateral 1.8 mm, and depth 1.8 mm, respectively ), and were chosen as areas for the cortical and subcortical tissues in the R6/2 mouse brain (Cummings et al., 2009; Zacharoff et al., 2012), respectively. For testing permeability using Evans Blue (EB), HD and WT mice of 12 weeks were intravenously injected with EB dye (4%, 4 ml/kg), and sacrificed 2 h post injection to harvest the brain. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cerebral microvascular aberrations have recently become recognized as a source of pathologies in neurodegenerative disorders, but this concept has not been fully examined with respect to Huntington's disease (HD). A novel in vivo technique, three-dimensional microscopic magnetic resonance angiography (μMRA), allows visualization of the neurovascular system in exquisite detail and provides quantitative structural and functional information. This technique was applied in the present study, in parallel with immunohistological analysis and behavioral assessment, to a well-characterized mouse model of HD (R6/2). Dynamic contrast-enhanced magnetic resonance imaging was used to examine the integrity of the blood-brain barrier (BBB). The μMRA findings revealed an increase in vessel volume fraction and cerebral blood volume in the brains of R6/2 mice at the age of 7weeks when no apparent motor dysfunction was detected. Collagen IV immunostaining disclosed an enhancement in vessel density, but not in vessel size of the microvasculature in the mouse HD brain. This change in neurovasculature worsened with disease progression, with no apparent disruption in the BBB. Most importantly, immunohistological assays of human tissues revealed that the vessel densities in the cortex, caudate/putamen, and substantia nigra were higher in HD patients than in non-HD human subjects. The early onset of such vessel aberrations could be used as a biomarker for the early diagnosis of HD.
    Experimental Neurology 09/2013; 250. DOI:10.1016/j.expneurol.2013.08.019 · 4.62 Impact Factor
  • Source
    • "se neuronal circuits is central to the development of motor and cog - nitive deficits characteristic of Huntington ' s disease ( Cepeda et al . , 2007 ) . In vitro studies in R6 / 2 mouse brain slices have also iden - tified hyperexcitability in both striatal medium spiny neurons ( Klapstein et al . , 2001 ) and within cortical pyramidal neurons ( Cummings et al . , 2009 ) . Increased neuronal excitability may result from the loss of inhibition regulating striatal and cortical neurons that may include fast spiking parvalbumin interneurons which are known to generate gamma oscillations ( Bracci et al . , 2003 ) . Alternatively , hyperexcitability and gamma oscillations in R6 / 2 mice may be a result of t"
    [Show abstract] [Hide abstract]
    ABSTRACT: Deficits in sleep and circadian organization have been identified as common early features in patients with Huntington's disease that correlate with symptom severity and may be instrumental in disease progression. Studies in Huntington's disease gene carriers suggest that alterations in the electroencephalogram may reflect underlying neuronal dysfunction that is present in the premanifest stage. We conducted a longitudinal characterization of sleep/wake and electroencephalographic activity in the R6/2 mouse model of Huntington's disease to determine whether analogous electroencephalographic 'signatures' could be identified early in disease progression. R6/2 and wild-type mice were implanted for electroencephalographic recordings along with telemetry for the continuous recording of activity and body temperature. Diurnal patterns of activity and core body temperature were progressively disrupted in R6/2 mice, with a large reduction in the amplitude of these rhythms apparent by 13 weeks of age. The diurnal variation in sleep/wake states was gradually attenuated as sleep became more fragmented and total sleep time was reduced relative to wild-type mice. These genotypic differences were augmented at 17 weeks and evident across the entire 24-h period. Quantitative electroencephalogram analysis revealed anomalous increases in high beta and gamma activity (25-60 Hz) in all sleep/wake states in R6/2 mice, along with increases in theta activity during both non-rapid eye movement and rapid eye movement sleep and a reduction of delta power in non-rapid eye movement sleep. These dramatic alterations in quantitative electroencephalographic measures were apparent from our earliest recording (9 weeks), before any major differences in diurnal physiology or sleep/wake behaviour occurred. In addition, the homeostatic response to sleep deprivation was greatly attenuated with disease progression. These findings demonstrate the sensitivity of quantitative electroencephalographic analysis to identify early pathophysiological alterations in the R6/2 model of Huntington's disease and suggest longitudinal studies in other preclinical Huntington's disease models are needed to determine the generality of these observations as a potential adjunct in therapeutic development.
    Brain 07/2013; 136(Pt 7):2159-2172. DOI:10.1093/brain/awt132 · 10.23 Impact Factor
Show more